TXNIP inhibition in the treatment of type 2 diabetes mellitus: design, synthesis, and biological evaluation of quinazoline derivatives

TXNIP inhibition in the treatment of type 2 diabetes mellitus: design, synthesis, and biological evaluation of quinazoline derivatives

AbstractThioredoxin interacting protein (TXNIP) is a potential drug target for type 2 diabetes mellitus (T2DM) treatment. A series of quinazoline derivatives were designed, synthesised, and evaluated to inhibit TXNIP expression and protect from palmitate (PA)-induced β cell injury. In vitro cell via...

Full description

Bibliographic Details
Main Authors: Aiyun Li, Li Guan, Wanzhen Su, Ning Zhao, Xuwen Song, Jin Wang, Xiaoxiao Tang, Weize Li, Xiangying Jiao
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
Quinazoline derivatives
TXNIP inhibition
oxidative stress and inflammation
pancreatic β cell apoptosis
T2DM
Online Access:https://www.tandfonline.com/doi/10.1080/14756366.2023.2166937

Internet

https://www.tandfonline.com/doi/10.1080/14756366.2023.2166937

Similar Items